Fig. 5From: The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney diseaseEvolution of mean health state utility, undiscounted health state costs and associated absolute NMB (WTP at £20,000 per QALY gained) over 20 years in surviving CKD patients. CKD chronic kidney disease, ESRD end stage renal disease, NMB net monetary benefit, QALY quality-adjusted life-year, RRT renal replacement therapy, WTP willingness-to-pay thresholdBack to article page